3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
20
Docetaxel
8
Carboplatin
8
Fluorouracil
6
Cisplatin
6
Nivolumab
5
fludarabine
4
Trastuzumab
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Cyclophosphamide
4
Biopsy
4
Bevacizumab
4
fludarabine phosphate
3
durvalumab
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
tisotumab vedotin
2
spartalizumab
2
belinostat
2
adavosertib
2
X-Rays
2
Vorinostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Diphenhydramine
×
Head & Neck
×
Clear all
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled